Alex Sirois |
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket
When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played…